ES2192832T3 - Uso de compuestos macrolidos para tratar glaucoma. - Google Patents

Uso de compuestos macrolidos para tratar glaucoma.

Info

Publication number
ES2192832T3
ES2192832T3 ES99905206T ES99905206T ES2192832T3 ES 2192832 T3 ES2192832 T3 ES 2192832T3 ES 99905206 T ES99905206 T ES 99905206T ES 99905206 T ES99905206 T ES 99905206T ES 2192832 T3 ES2192832 T3 ES 2192832T3
Authority
ES
Spain
Prior art keywords
compounds
treat glaucoma
macrolid
macrolid compounds
glaucoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99905206T
Other languages
English (en)
Inventor
Shozo Sakuma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP1955A external-priority patent/AUPP195598A0/en
Priority claimed from AUPP2992A external-priority patent/AUPP299298A0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2192832T3 publication Critical patent/ES2192832T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Abstract

Esta invención proporciona un nuevo uso de los compuestos de macrólido para prevenir o tratar glaucoma. Adicionalmente, esta invención proporciona un agente profiláctico o terapéutico para el glaucoma, que comprende los compuestos de macrólido.
ES99905206T 1998-02-23 1999-02-17 Uso de compuestos macrolidos para tratar glaucoma. Expired - Lifetime ES2192832T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP1955A AUPP195598A0 (en) 1998-02-23 1998-02-23 New use
AUPP2992A AUPP299298A0 (en) 1998-04-16 1998-04-16 New use

Publications (1)

Publication Number Publication Date
ES2192832T3 true ES2192832T3 (es) 2003-10-16

Family

ID=25645716

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99905206T Expired - Lifetime ES2192832T3 (es) 1998-02-23 1999-02-17 Uso de compuestos macrolidos para tratar glaucoma.

Country Status (9)

Country Link
US (1) US6384073B1 (es)
EP (1) EP1056454B1 (es)
JP (1) JP2002503692A (es)
AT (1) ATE238792T1 (es)
DE (1) DE69907418T2 (es)
DK (1) DK1056454T3 (es)
ES (1) ES2192832T3 (es)
PT (1) PT1056454E (es)
WO (1) WO1999042104A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7265150B1 (en) * 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US7338976B1 (en) * 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1227859B1 (en) * 1999-11-12 2006-08-09 Alcon, Inc Neurophilin ligands for treating ocular conditions
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds
WO2003061519A2 (en) * 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US7592330B2 (en) * 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
WO2008042216A2 (en) 2006-09-28 2008-04-10 Follica, Inc. Methods, kits, and compositions for generating new hair follicles and growing hair
KR20090094090A (ko) * 2006-12-28 2009-09-03 리머릭 바이오파르마 인코오포레이티드 치료를 위한 방법 및 조성물
WO2008127746A1 (en) 2007-01-10 2008-10-23 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
MX2010001141A (es) * 2007-07-31 2010-03-01 Limerick Biopharma Inc Analogos fosforiladosde pirona y metodos.
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
WO2012118863A1 (en) * 2011-02-28 2012-09-07 The Schepens Eye Research Institute, Inc. Therapies that target autoimmunity for treating glaucoma and optic neuropathy
US10428331B2 (en) 2014-01-16 2019-10-01 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
EP0581959B1 (en) * 1991-04-26 2001-01-17 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for eye diseases
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
WO1997031020A1 (en) * 1996-02-22 1997-08-28 The General Hospital Corporation METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
US5994388A (en) * 1997-03-18 1999-11-30 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis

Also Published As

Publication number Publication date
DE69907418D1 (de) 2003-06-05
US6384073B1 (en) 2002-05-07
WO1999042104A1 (en) 1999-08-26
EP1056454B1 (en) 2003-05-02
JP2002503692A (ja) 2002-02-05
DK1056454T3 (da) 2003-08-18
EP1056454A1 (en) 2000-12-06
PT1056454E (pt) 2003-08-29
ATE238792T1 (de) 2003-05-15
DE69907418T2 (de) 2003-11-13

Similar Documents

Publication Publication Date Title
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
PT842934E (pt) Agonistas de 5-ht1f
DK0915898T3 (da) Krystalform I af clarithromycin
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
ATE468889T1 (de) Kosmetische zusammensetzung zur behandlung von alternder und/oder gestresster haut
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
ES2080297T3 (es) Derivados 17-g(b)-sustituido-4-aza-5g(a)-androstan-3-ona y procedimiento de preparacion de estos.
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BR0015392A (pt) Lipoxina a4 e seus análogos para o tratamento de olho ressecado
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
BR0011225A (pt) Agente para tratar de olhos secos, seu método e uso
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
AU2001289714A1 (en) Benzofuran derivatives and their use as antibacterial agents
BR9908796A (pt) Uso de compostos de macrolìdeo, método de tratamento e prevenção de ards, composição farmacêutica e composto macrolìdeo
BR0009194A (pt) Composição do resorcinol
RU94045256A (ru) Применение бензо[g]хинолинов
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
ES2082212T3 (es) Nuevos inhibidores de alfa-glucosidasa.
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
BR9507732A (pt) Composição farmacêutica para o tratamento de glaucoma